Country: Israel
Language: English
Source: Ministry of Health
PURIFIED FISH OIL; REFINED OLIVE OIL; SOYA OIL; TRIGLYCERIDES, MEDIUM-CHAIN
CURE MEDICAL & TECHNICAL SUPPLY
B05BA10
EMULSION FOR INFUSION
TRIGLYCERIDES, MEDIUM-CHAIN 60 G/L; SOYA OIL 60 G/L; REFINED OLIVE OIL 50 G/L; PURIFIED FISH OIL 30 G/L
I.V
Required
FRESENIUS KABI AB, SWEDEN
COMBINATIONS
COMBINATIONS
Supply of energy and essential fatty acids and omega-3 fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated
2022-12-31
לע העדוה לע העדוה לע העדוה ( הרמחה ( הרמחה ( הרמחה עדימ עדימ עדימ ל ןולעב )תוחיטב ל ןולעב )תוחיטב ל ןולעב )תוחיטב אפור אפור אפור ןכדועמ( ןכדועמ( ןכדועמ( .102.50 .102.50 .102.50 ) ) ) ךיראת : 07.03.16 תילגנאב רישכת םש םושירה רפסמו : ) 137 75 31387 ) SMOFLIPID םושירה לעב םש : יילפוס לקינקט דנא לקידמ רויק מ"עב ה טורפל דעוימ הז ספוט דבלב תורמחה ! תושקובמה תורמחהה ןולעב קרפ יחכונ טסקט שדח טסקט QUALITATIVE AND QUANTITATIVE COMPOSITION -------------- Excipients with known effect: 1000 ml emulsion contains up to 5 mmol sodium (as sodium hydroxide and sodium oleate). SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE -------- --- Smoflipd contains up to 5 mmol sodium per 1000 ml. To be taken into consideration by patients on a controlled sodium diet. ב"צמ נמוסמ ובש ,ןולעה תו תורמחהה שקובמה תו בוהצ עקר לע . ונמוס תורמחה רדגב םניאש םייוניש )ןולעב( תוהמ ןכות קר ןמסל שי .הנוש עבצב םוקימב םייוניש אלו י .טסקטה Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT SMOFlipid 200 mg/ml emulsion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1000 ml of emulsion for infusion contain: Soya-bean oil, refined 60.0 g Triglycerides, medium-chain 60.0 g Olive oil, refined 50.0 g Fish oil, rich in omega-3-acids 30.0 g Total energy: 8.4 MJ/l (= 2000kcal/l) pH-value: approx. 8 Osmolality approx. 380 mosm/kg Excipients with known effect: 1000 ml emulsion contains up to 5 mmol sodium (as sodium hydroxide and sodium oleate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Emulsion for infusion. White homogenous emulsion. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Supply of energy and essential fatty acids and omega-3 fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contraindicated. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The patient’s ability to eliminate the fat infused, should govern the dosage and infusion rate, see section 4.4. Adults The standard dose is 1.0 – 2.0 g fat/kg body weight (b.w.)/day, corresponding to 5 – 10 ml/kg b.w./day. The recommended infusion rate is 0.125 g fat/kg b.w./hour, corresponding to 0.63 ml Smoflipid/kg b.w./hour, and should not exceed 0.15 g fat/kg b.w./hour, corresponding to 0.75 ml Smoflipid/kg b.w./hour. _Paediatric population _ _ _ Neonates and infants The initial dose should be 0.5 – 1.0 g fat/kg b.w./day followed by a successive increase by 0.5 – 1.0 g fat/kg b.w./day up to 3.0 g fat/kg b.w./day. It is recommended not to exceed a daily dose of 3 g fat/kg b.w./d, corresponding to 15 ml Smoflipid/kg b.w./day. The rate of infusion should not exceed 0.125 g fat/kg b.w./hour. In premature and low birthweight neonates, Smoflipid should be infused continuously over about 24 hours. The duration of treatment should not exceed 30 days. Children It is recommended not to exceed a daily dose of 3 g fat/kg b.w./d, corresponding to 15 ml Smoflipid/kg b.w Read the complete document